CergenX

CergenX develops an AI platform that analyses neonatal EEG to provide bedside clinical assessments for newborn brain injury risk. The company focuses on making EEG-derived insights accessible to non-specialist clinicians, and its Wave product is CE marked with FDA clearance pending, not for sale in the US.

Description written by StartupJobs from the company's website.